1. Home
  2. NGNE vs WLKP Comparison

NGNE vs WLKP Comparison

Compare NGNE & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$38.24

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo Westlake Chemical Partners LP

WLKP

Westlake Chemical Partners LP

HOLD

Current Price

$21.90

Market Cap

762.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
WLKP
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
762.4M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
NGNE
WLKP
Price
$38.24
$21.90
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$63.57
N/A
AVG Volume (30 Days)
193.8K
28.5K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
8.25%
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
$1,166,695,000.00
Revenue This Year
N/A
$19.48
Revenue Next Year
N/A
$5.24
P/E Ratio
N/A
$15.30
Revenue Growth
N/A
2.71
52 Week Low
$15.93
$17.75
52 Week High
$43.66
$23.88

Technical Indicators

Market Signals
Indicator
NGNE
WLKP
Relative Strength Index (RSI) 56.17 60.21
Support Level $18.00 $21.43
Resistance Level $42.84 $22.26
Average True Range (ATR) 2.40 0.37
MACD -0.07 0.06
Stochastic Oscillator 51.32 81.73

Price Performance

Historical Comparison
NGNE
WLKP

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About WLKP Westlake Chemical Partners LP

Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products, such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen, to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.

Share on Social Networks: